language_icon
EN
HI

Thyrocare Technologies Share price

THYROCARE

475

5.85 (-1.22%)
NSE
BSE
Last updated on 12 May, 2026 | 15:57 IST
Today's High

480.90

Today's Low

466.30

52 Week Low

291.37

52 Week High

536.67

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Thyrocare Technologies Chart

Thyrocare Technologies Share Key Metrics

Volume
4.45 L
Market Cap
7560.35 CR
LTQ@LTP
25@475.00
ATP
475.29
Var Margin
19.83 %
Circuit Range
384.7-577
Delivery %
39.45 %
Value
21.16 CR
ASM/GSM
No
Market Lot
1

Summary

Thyrocare Technologies share price stands at ₹475 at 12 May, 2026 | 15:57. The stock Thyrocare Technologies intraday movement has stayed between ₹466.30 and ₹480.90, while on a 52-week basis it has fluctuated from ₹291.37 to ₹536.67.
In terms of trading activity, Thyrocare Technologies has recorded a volume of 445264 shares. The Thyrocare Technologies has a market cap of ₹159165315. The stock’s Average Traded Price (ATP) stands at ₹47529, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 25, 47500.
The Thyrocare Technologies operates within a circuit range of ₹384.7-577 – ₹384.7-577, with a Value of ₹21.16 CR. The Delivery Percentage for the day is 39.45%. Additionally, Thyrocare Technologies currently falls under the No framework, and trades with a market lot size of 1.

Thyrocare Technologies Fundamentals

View More
P/E Ratio

47.39

P/B Ratio

13.2

Div. Yield

2.88

Sector P/E

56.71

Sector P/B

-15.83

Sec. Div. Yield

1.86

Thyrocare Technologies Resistance and Support

Pivot 482.95

Resistance

First Resistance

488.85

Second Resistance

496.85

Third Resistance

502.75

Support

First Support

474.95

Second Support

469.05

Third Support

461.05

Thyrocare Technologies Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

60.92%

Mutual Fund

19.45%

Insurance

0.37%

Foreign Institutional Investors

5.37%

Domestic Institutional Investors

1.17%

Retail

12.71%

Others

0.01%

Total Promoters
MAR '26
60.92%

Thyrocare Technologies Corporate Actions

DateAgenda
2026-05-07Audited Results & Final Dividend
2026-01-28Quarterly Results
2025-10-14Qtr Results
2025-07-23Quarterly Results
2025-04-23Audited Results & Final Dividend
2025-01-23Quarterly Results

Thyrocare Technologies News

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Thyrocare Technologies announced the audio recording of its earnings conference call, held on May 12, 2026, for the quarter and financial year ended March 31, 2026, is now available on the company's website for investor access. The transcript will be shared shortly.
May 12 2026 14:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

Thyrocare Technologies' Board approved altering its Memorandum of Association (MOA) to broaden the company's business scope within the healthcare and diagnostics ecosystem. This change, pending shareholder approval, enables the company to undertake a wider range of activities, including allied services and related products.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Appointment Of Cost Auditors For The Financial Year 2026-27

Thyrocare's Board met on May 7, 2026, and recommended a final dividend of Rs. 7.00 per share for FY2025-26. The board also approved the appointment of new statutory and cost auditors, re-appointment of MD & CEO, and made changes to other directors.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

Thyrocare Technologies' board approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as statutory auditors for a five-year term. This appointment is subject to shareholder approval at the upcoming AGM.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Change in Directorate

Thyrocare Technologies re-appointed Mr. Rahul Franklin Guha as Chairman, Managing Director & CEO for a five-year term, effective May 4, 2027, subject to shareholder approval. This ensures continued leadership for strategic initiatives.
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Corporate Action-Board approves Dividend

Thyrocare board recommended a final dividend of ₹7.00 per equity share for FY26. Including the interim dividend, the total payout for the fiscal year amounts to ₹9.33 per share (post bonus adjustment).
May 07 2026 19:05:00

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Thyrocare Technologies announced robust Q4 FY26 consolidated results, with revenue growing 20% YoY to Rs.223.95 cr and net profit soaring 128% YoY to Rs.48.70 cr. The company also reported strong annual growth for FY26.
May 07 2026 18:05:00

Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 07, 2026

Thyrocare Technologies board approved its FY26 audited financial results and recommended a final dividend of ₹7.00 per equity share. The board also re-appointed Rahul Guha as CMD for five years and approved a ₹5.50 crore investment in its wholly-owned subsidiary, Think Health Diagnostics Private Limited.
May 07 2026 17:05:00

Thyrocare Technologies Ltd - 539871 - Cancellation Of Earning Conference Call

Thyrocare Technologies announced the cancellation of its earnings conference call for analysts/investors, which was scheduled for May 07, 2026. The call was intended to discuss the company's Audited Financial Results for Q4 and FY26. A revised schedule will be provided later.
May 07 2026 17:05:00

Thyrocare Technologies Ltd - 539871 - Corporate Action-Board to consider Dividend

Thyrocare Technologies board to meet on May 07, 2026, to consider a final dividend for FY 2025-26. This decision is crucial for shareholder returns.
Apr 29 2026 13:04:00
Read More

About Thyrocare Technologies

NSE : 17032  
BSE : 539871  
ISIN : INE594H01019  

The Company was incorporated as Thyrocare Technologies Limited on January 28 2000 at Mumbai as a public limited company under the Companies Act 1956. the Company was issued a certificate of commencement of business from the RoC on March 7 2000. Major events and milestones of the Company :2000-The Company was incorporated in the name and style of "Thyrocare Technologies Limited? and received a certificate for commencement of operations. 2001-The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005-The Company received NABL accreditation. 2006-The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007-The Company receives accreditation from the College of American Pathologists (CAP). 2010-The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011-The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012-NVP acquired certain Equity Shares aggregating to 1200 million from certain entities. 2013-EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1000 scans in the first year of operation. 2014-The Company had installed India?s first and the world?s longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1000 scans in the first year of operations. 2015-The Company opened RPLs in Delhi Coimbatore Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests at present include physical and chemical testing elements testing microbiology testing pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10000 scans at the PET-CT centres in New Delhi over 10000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1000 scans at the PET-CT centres in Hyderabad since inception.

Read More

Thyrocare Technologies Management

NamePosition
Brijesh KumarCompany Secretary & Compliance Officer
Rahul GuhaManaging Director & Chief Executive Officer
View More

Thyrocare Technologies FAQs

The Buying Price of Thyrocare Technologies share is 475 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Thyrocare Technologies stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Thyrocare Technologies, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Thyrocare Technologies shares is 47.39. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Thyrocare Technologies shares is 13.2. Useful to assess the stock's value relative to its book value.

To assess Thyrocare Technologies’s valuation compare Sector P/E, P/B which are 56.71 & -15.83 with sector averages, along with growth rates and financial metrics.

The Market Cap of Thyrocare Technologies is 7560.35 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Thyrocare Technologies share price is 536.67 & 291.37. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Thyrocare Technologies belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost